Protara Therapeutics Inc (TARA NASDAQ) stock market data APIs
$3.2253
0.18(5.6%)
as of May 21, 2025
Try our APIs with
free plan!
Protara Therapeutics Inc Financial Data Overview
Prev. Close
3.2253
Open
3.4082
High
3.5001
Low
3.2095
52 wk Range
1.595-6.8799
Market Cap
134 M
Shares Outstanding
38 582 K
EPS
-0.29
Beta
1.72
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Protara Therapeutics Inc data using free add-ons & libraries
Get Protara Therapeutics Inc Fundamental Data
{
"General": {
"Code": "TARA",
"Type": "Common Stock",
"Name": "Protara Therapeutics Inc",
"Exchange": "NASDAQ",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG001ZLYSH5",
"ISIN": null,
"CUSIP": null,
"CIK": "0001359931",
"EmployerIdNumber": null,
"FiscalYearEnd": "December",
"IPODate": "2014-10-22",
"InternationalDomestic": null,
"Sector": "Healthcare",
"Industry": "Biotechnology",
"HomeCategory": "Domestic",
"IsDelisted": false,
"Description": "Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-m..."
}
}Protara Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -51 095 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: -0.4775
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Protara Therapeutics Inc News
New
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month eval...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treat...
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients TARA-002 demonstrates 76% complete response rate at any time...
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
